Quantum Biopharma (QNTM) Notes Payables (2019 - 2026)
Quantum Biopharma (QNTM) posted Notes Payables of $300549.0 for Q1 2026, down 76.89% sequentially from $1.3 million in Q4 2025, and down 72.37% YoY from $1.1 million in Q1 2025.
Quantum Biopharma (QNTM) Notes Payables (2019 - 2026) Analysis & Trends
Quantum Biopharma has reported Notes Payables for 8 years, with the latest figure at $300549.0 in Q1 2026.
- Quarterly Notes Payables fell 72.37% year-over-year to $300549.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $300549.0 (down 72.37% YoY) and the FY2025 annual result came in at $1.3 million, up 110.1% from the prior year.
- Notes Payables eased to $300549.0 in Q1 2026 per QNTM's latest filing, from $1.3 million in the prior quarter.
- Over five years, Notes Payables peaked at $2.0 million in Q3 2025 and troughed at $300549.0 in Q1 2022.
- A 5-year average of $683187.2 and a median of $300549.0 in 2022 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2025 and 2026: Notes Payables soared 557.23% in 2025, then sank 72.37% in 2026.
- Over 5 years, Notes Payables stood at $300549.0 in 2022, then changed by 0.0% to $300549.0 in 2023, then jumped by 105.97% to $619029.0 in 2024, then jumped by 110.1% to $1.3 million in 2025, then slumped by 76.89% to $300549.0 in 2026.
- According to Business Quant data, Notes Payables over the past three periods registered $300549.0, $1.3 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - |
| 10 | Quantum Biopharma | 15.25 Mn | 11.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,549.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 619,029.00 |
| Sep 30, 2024 | 300,549.00 |
| Jun 30, 2024 | 615,562.00 |
| Sep 30, 2023 | 300,549.00 |
| Jun 30, 2023 | 300,549.00 |
| Mar 31, 2023 | 300,549.00 |
| Dec 31, 2022 | 300,549.00 |
| Sep 30, 2022 | 300,549.00 |
| Jun 30, 2022 | 300,549.00 |
| Mar 31, 2022 | 300,549.00 |
| Dec 31, 2021 | 300,549.00 |
| Sep 30, 2021 | 300,549.00 |
| Jun 30, 2021 | 300,549.00 |
| Mar 31, 2021 | 358,549.00 |
| Dec 31, 2020 | 384,647.00 |